The short version
- What the evidence isApproved for anemia of chronic kidney disease in China, Japan and the European Union.
- What to watchA swollen painful calf, sudden breathlessness or chest pain.
How Roxadustat works
The oxygen sensor, named. Hypoxia-inducible factor is a transcription factor built from an alpha subunit and a beta subunit.
What survives, and what it turns on. Stabilized HIF drives erythropoietin transcription in kidney and liver, and it does something injected erythropoietin cannot: it suppresses hepcidin, the liver peptide that locks iron inside macrophages and enterocytes, while upregulating the transporters and ferroxidases that move iron into plasma. That is why the meta-analysis comparing this class with erythropoiesis-stimulating agents finds a different iron picture rather than merely a different route Zheng 2023.
Block them and HIF survives in a normally oxygenated cell, which is chemically the same signal a body reads at altitude: erythropoietin transcription rises from kidney and liver, hepcidin falls so stored iron is released, and iron-handling proteins are upregulated together rather than singly. That coordinated iron effect is the real difference from injected erythropoietin, which raises the demand for iron without doing anything about the supply.
- Oral
On the goal map: Oxygen delivery & nitric oxide (Endurance & work capacity)
Research on Roxadustat7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Approved for anemia of chronic kidney disease in China, Japan, the EU and elsewhere; the FDA declined it in 2021. Prohibited in sport.
Human clinical evidence
Approved for anemia of chronic kidney disease in China, Japan and the European Union. The FDA declined it in 2021. Same molecule, same trial program, different verdicts.
More than 27,228 patients have been studied across the HIF stabilizer class, and a 2023 nephrology commentary is titled around the fact that its role is still undefined (Fishbane 2023).
Network meta-analysis across dialysis and non-dialysis populations establishes the hemoglobin response (Sackeyfio 2024); a separate systematic review exists specifically to address cardiovascular and renal safety (Tian 2024), which is not a paper anyone writes about a drug whose safety is settled.
Correlative data
Compared against erythropoiesis-stimulating agents in dialysis patients, this class shows a different iron picture rather than only a different route — hepcidin suppression mobilizes stored iron (Zheng 2023).
It is prohibited in sport and the assays are published: a novel methylated metabolite identified by metabolomics (Saigusa 2018), and detection of the whole class in hair and nails (Checkouri 2024).
How the mechanism reads
Every patient in every trial had failing kidneys. The drug restores a deficient erythropoietin signal toward normal. A person with healthy kidneys has no deficient signal to restore, and no trial has ever been run in that person.
MechanisticHIF regulates VEGF and the glycolytic program as well as erythropoietin, so stabilizing it systemically turns on a response the body normally runs only where oxygen is low. That breadth is the root of the unresolved safety question.
Mechanistic
Sources
- Czock D, Keller F. Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat. Clinical Pharmacokinetics 2022 · PMID 34905154
- Tian L, Wang M, Liu M, Pang Y, Zhao J, Zheng B, Wang Y, Zhao W. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis. Renal Failure 2024 · PMID 38345037
- Fishbane S, Malieckal DA, Ng JH. Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefined. Clinical Kidney Journal 2023 · PMID 37151410
- Zheng Q, Zhang P, Yang H, Geng Y, Tang J, Kang Y, Qi A, Li S. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis. Heliyon 2023 · PMID 37123954
- Sackeyfio A, Lopes RD, Kovesdy CP, Cases A, Mallett SA, Ballew N, Keeley TJ, Garcia-Horton V, Ayyagari R, Camejo RR, Johansen KL, Sutton AJ, Dasgupta I. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors in anemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations. Clinical Kidney Journal 2024 · PMID 38250252
- Saigusa D, Suzuki N, Matsumoto Y, Umeda K, Tomioka Y, Koshiba S, Yamamoto M. Detection of novel metabolite for Roxadustat doping by global metabolomics. Journal of Biochemistry 2018 · PMID 29438490
- Checkouri A, Gheddar L, Arbouche N, Raul JS, Kintz P. Simultaneous detection of three hypoxia-inducible factor stabilizers: molidustat, roxadustat, and vadadustat: in multiple keratinized matrices and its application in a doping context. Drug Testing and Analysis 2024 · PMID 38992954
- Thevis M, Kuuranne T, Geyer H. Annual Banned-Substance Review 18th Edition: Analytical Approaches in Human Sports Drug Testing 2024/2025. Drug Testing and Analysis 2026 · PMID 41702393
Roxadustat safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Past clot, stroke or heart attack: higher red cell mass and platelets raise thrombosis risk.
- Any cancer, or unexplained mass: HIF stabilization also feeds VEGF and EPO signals in tumors.
- Uncontrolled high blood pressure or polycythemia.
- Proliferative eye disease: VEGF rise can worsen abnormal retinal vessels.
- Tested sport: HIF stabilizers are prohibited by WADA.
What’s expected
- Rising hemoglobin, since HIF drives EPO and lowers hepcidin so iron is released.
- Higher blood pressure and thicker blood as red cells rise.
- Headache, or flushed face.
- Swelling in hands or feet.
Watch for
- A swollen painful calf, sudden breathlessness or chest pain.
- Face drooping, weakness or slurred speech.
- Severe headache or a seizure.
- Vision change.
Labs that tell you it’s working
- Complete Blood Count (CBC) w/ Differential
- Iron Panel (Iron, TIBC, UIBC, Sat%)
- Ferritin
- D-Dimer
Roxadustat inhibits HIF prolyl-hydroxylases, mimicking altitude: EPO up, hepcidin down; red cell mass, iron and clotting markers are the readout. PMID 38345037
Also on the record
- Prescription-only. Approved for anemia of chronic kidney disease in China, Japan and the EU; the FDA declined it in 2021 over the cardiovascular safety question. Prohibited in sport, and detectable in hair and nails long after blood and urine clear.
Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Roxadustat FAQ3 common questions
- Is Roxadustat approved for human use?
- Roxadustat is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- Which labs show whether it's doing anything?
- Complete Blood Count; Iron Panel; Ferritin; D-Dimer: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Roxadustat: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



